Catalyst Biosciences Inc (CBIO) : Dg Capital Management reduced its stake in Catalyst Biosciences Inc by 70.86% during the most recent quarter end. The investment management company now holds a total of 45,265 shares of Catalyst Biosciences Inc which is valued at $61,108 after selling 110,087 shares in Catalyst Biosciences Inc , the firm said in a disclosure report filed with the SEC on Aug 15, 2016.Catalyst Biosciences Inc makes up approximately 0.15% of Dg Capital Management’s portfolio.
Other Hedge Funds, Including , Group One Trading added CBIO to its portfolio by purchasing 2,679 company shares during the most recent quarter which is valued at $3,617.Blackrock Institutional Trust Company N.a. reduced its stake in CBIO by selling 692 shares or 0.43% in the most recent quarter. The Hedge Fund company now holds 161,419 shares of CBIO which is valued at $217,916. Wedbush Securities Inc added CBIO to its portfolio by purchasing 13,475 company shares during the most recent quarter which is valued at $19,943.
Many Wall Street Analysts have commented on Catalyst Biosciences Inc. Rodman & Renshaw Initiated Catalyst Biosciences Inc on Jun 30, 2016 to “Buy”, Price Target of the shares are set at $3.50.
Catalyst Bioscience Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis including the treatment of hemophilia and surgical bleeding and inflammation including prevention of delayed graft function in renal transplants and the treatment of dry age-related macular degeneration a condition that can cause visual impairment or blindness. The Company’s advanced program is a coagulation Factor VIIa variant CB 813d which has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition it has two other coagulation factors a Factor IX variant CB 2679d/ISU 304 which is in advanced preclinical development and a Factor Xa variant which is in the advanced lead stage of development. Its second area of focus is regulation of the complement cascade.